Psychometric validation of the consensus five-factor model of the Positive and Negative Syndrome Scale

Fong, Ted C. T.; Ho, Rainbow T. H.; Wan, Adrian H. Y.; Siu, Pantha Joey Chung Yue; Au-Yeung, Friendly S.W.

doi:10.1016/j.comppsych.2015.07.015

Cited by 21 publications

(12 citation statements)

References 27 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The strengths of the current study include the large study sample, which is the largest so far in the literature investigating the factor structure of the PANSS as well as efforts to clinically stage schizophrenia. In contrast to other studies, we did not exclude any basic component of the disease’s symptomatology (Kelley et al, 2013; Khan et al, 2013a, 2013b; Fong et al, 2015; Wu et al, 2015). An additional strength is the multi-center and multinational characteristic of the sample.…”

Section: Discussionmentioning

confidence: 99%

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study

Fountoulakis

Dragioti²,

Antonis

et al. 2019

International Journal of Neuropsychopharmacology

View full text Add to dashboard Cite

IntroductionA specific clinically relevant staging model for schizophrenia has not yet been developed. The aim of the current study was to evaluate the factor structure of the PANSS and develop such a staging method.MethodsTwenty-nine centers from 25 countries contributed 2358 patients aged 37.21 ± 11.87 years with schizophrenia. Analysis of covariance, Exploratory Factor Analysis, Discriminant Function Analysis, and inspection of resultant plots were performed.ResultsExploratory Factor Analysis returned 5 factors explaining 59% of the variance (positive, negative, excitement/hostility, depression/anxiety, and neurocognition). The staging model included 4 main stages with substages that were predominantly characterized by a single domain of symptoms (stage 1: positive; stages 2a and 2b: excitement/hostility; stage 3a and 3b: depression/anxiety; stage 4a and 4b: neurocognition). There were no differences between sexes. The Discriminant Function Analysis developed an algorithm that correctly classified >85% of patients.DiscussionThis study elaborates a 5-factor solution and a clinical staging method for patients with schizophrenia. It is the largest study to address these issues among patients who are more likely to remain affiliated with mental health services for prolonged periods of time.

show abstract

Section: Discussionmentioning

confidence: 99%

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study

Fountoulakis

Dragioti²,

Antonis

et al. 2019

International Journal of Neuropsychopharmacology

View full text Add to dashboard Cite

show abstract

“…Other instruments such as Clinical Global Impression and Positive and Negative Syndrome Scale (PANSS) were used to assess response to treatment. 30 , 31 Data were retrospectively collected, including all reliable AP assays from medical files and through interviews with the attending psychiatrist of each patient. By using this information, we allocated the patients of each group, according to their level of AP response.…”

Section: Methodsmentioning

confidence: 99%

Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia

Escamilla¹,

Camarena²,

Saracco-Álvarez³

et al. 2018

NDT

View full text Add to dashboard Cite

PurposeThe efficacy of schizophrenia treatments using antipsychotics (APs) has long been established, but the benefit obtained by several patients using conventional APs (typical or atypical) has not been enough. Currently, the genetic study of the primary mechanisms of action of the APs has been focused on the dopaminergic pathways. The objective of this study was to determine if the response phenotypes (responder, resistance to treatment, and ultra-resistance to treatment groups) are associated with six single-nucleotide polymorphisms: COMT (Val158Met), DRD2 (A-241G, C376G, C939T, Taq1A), and DRD3 (Ser9Gly).Patients and methodsWe classified the patients through a retrospective/prospective methodology to define response phenotypes.ResultsCOMT/Val158Met and DRD3/Ser9Gly were associated with the responder group (P<0.05). The single-nucleotide polymorphism A-241G of DRD2 gene was related with the resistant-to-treatment group (P<0.001). Finally, Met/Met of COMT and Ser/Gly of DRD3 genes showed a predictive effect associated with the resistant-to-treatment phenotype.ConclusionFurther analyses should be performed to validate these genetic markers as mediators for the response to APs.

show abstract

“…The reference list of these papers was also reviewed. A total of 33 reports across 16,171 participants were included in this analysis 6,8,9,18,19,55–79 . Characteristics of the included studies are presented in Supplementary Table 6.…”

Section: Resultsmentioning

confidence: 99%

“…16,17 Notable efforts were made to establish a consensus structure, to improve replicability and reproducibility of symptom measures. 17 While the five-factor consensus model have been validated in Brazilian 18 and Chinese 19,20 samples separately, few reports have evaluated transethnic PANSS symptom architecture. 21 Nevertheless, there has been much variability in the analytic approaches, dearth of independent sample validation, transethnic comparisons and sparse large scale reports that support the consensus factor structure of PANSS.…”

Section: Introductionmentioning

confidence: 99%

Large-Scale Evaluation of the Positive and Negative Syndrome Scale (PANSS) Symptom Architecture in Schizophrenia

Lim

Peh

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Although the Positive and Negative Syndrome Scale (PANSS) is widely utilized in schizophrenia research, variability in specific item loading exist, hindering reproducibility and generalizability of findings across schizophrenia samples. We aim to establish a common metric PANSS factor structure from a large multi-ethnic sample and validate it against a meta-analysis of existing PANSS models. Schizophrenia participants (N = 3511) included in the current study were part of the Singapore Translational and Clinical Research Program (STCRP) and the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE). Exploratory Factor Analysis (EFA) was conducted to identify the factor structure of PANSS and validated with a meta-analysis (N = 16,171) of existing PANSS models. Temporal stability of the PANSS model and generalizability to individuals at ultra-high risk (UHR) of psychosis were evaluated. A five-factor solution best fit the PANSS data. These were the i) Positive, ii) Negative, iii) Cognitive/disorganization, iv) Depression/anxiety and v) Hostility factors. Convergence of PANSS symptom architecture between EFA model and meta-analysis was observed. Modest longitudinal reliability was observed. The schizophrenia derived PANSS factor model fit the UHR population, but not vice versa. We found that two other domains, Social Amotivation (SA) and Diminished Expression (DE), were nested within the negative symptoms factor. Here, we report one of the largest transethnic factorial structures of PANSS symptom domains (N = 19,682). Evidence reported here serves as crucial consolidation of a common metric PANSS that could aid in furthering our understanding of schizophrenia.

show abstract

Psychometric validation of the consensus five-factor model of the Positive and Negative Syndrome Scale

Cited by 21 publications

References 27 publications

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study

Association study between <em>COMT</em>, <em>DRD2</em>, and <em>DRD3</em> gene variants and antipsychotic treatment response in Mexican patients with schizophrenia

Large-Scale Evaluation of the Positive and Negative Syndrome Scale (PANSS) Symptom Architecture in Schizophrenia

Contact Info

Product

Resources

About